
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated a positive financial trajectory, reporting 4Q25 revenues of $174.4 million, marking a 4% increase quarter-over-quarter and an 8% increase year-over-year for full-year 2025, with total revenue reaching $655.4 million. The growth is attributed to strong domestic sales of Optune Gio in the treatment of glioblastoma and significant contributions from international markets, highlighted by national reimbursement in Spain expected to drive future revenue gains. Additionally, ongoing clinical trials and a strategic sales force approach are anticipated to bolster the company's growth prospects in key cancer treatment areas, including non-small cell lung cancer and pancreatic cancer.
Bears say
NovoCure Ltd is experiencing a downward adjustment in revenue estimates for 2026, with projections for Glioblastoma (GBM) revenue reduced from $702 million to $690 million, while overall total revenue expectations have decreased from $738.9 million to $711.3 million. The company faces significant risks, including potential safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory concerns, and issues related to intellectual property protection. Additionally, challenges in the commercial rollout of its Non-small cell lung cancer (NSCLC) treatment have led to further downgrades in revenue estimates for both the U.S. and European markets, exemplifying the underlying vulnerabilities in NovoCure's financial outlook.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares